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TH1 cells have long been thought to be the major pathogenic cell population in organ-
specific autoimmune inflammation. As IL-18 is a vital cofactor, together with IL-12, in 
promoting TH1 development, we examined the role of IL-18 and its receptor in the context 
of autoimmune CNS-inflammation. As with IL-12-deficient mice, we found that IL-18-
deficient mice are fully susceptible to EAE. Surprisingly, we discovered that mice deficient 
in IL-18Rα are EAE-resistant, suggesting the presence of an alternative ligand with 
encephalitogenic properties. Our results establish that IL-18 and TH1 development are 
dispensable for autoimmune inflammation, while IL-18Rα engagement on APCs is essential 
for the generation of encephalitogenic TH17 cells which are now considered to be the major 
pathogenic population in autoimmune diseases. 
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Tissue-specific, cell-mediated autoimmune diseases, such as rheumatoid arthritis (RA), type I 
diabetes or multiple sclerosis (MS), are widely held to be mediated by autoreactive TH 
lymphocytes. Until recently, MS and RA were firmly recognized to be TH1-mediated, a notion 
supported by the findings obtained using their respective animal models, experimental 
autoimmune encephalomyelitis (EAE) and collagen-induced arthritis (CIA)1, 2. In EAE, for 
example, disease can be induced in susceptible rodents by adoptive transfer of myelin-reactive 
TH1 cells as well as by active immunization with myelin antigens. Nevertheless, the main 
evidence supporting that pathogenic autoimmune cells are polarized TH1 cells is based on the fact 
that tissue-invading T cells usually express IFN-γ3, 4. Furthermore, auto-aggressive TH2 cells were 
believed to have anti-encephalitogenic properties and immune deviation is considered an 
attractive therapeutic strategy5-7. However, a paradigm shift was initiated by a number of 
important key findings: i) IFN-γ- as well as TNF-α-deficient mice were found to be EAE 
susceptible8-11. In fact, IFN-γ-deficiency even renders EAE-resistant mouse strains susceptible to 
EAE9. ii) while the p40 subunit of IL-12 was found to be critical for the development of 
autoimmunity, its binding partner p35 was shown to be irrelevant12. This phenomenon is 
explained by the fact that p40 is also the large subunit of IL-23, which, in contrast to IL-12, is 
vital for autoimmunity12. iii) IL-23 is, compared to IL-12, not a major TH1 inducing cytokine but 
drives the expansion of IL-17-polarized T cells. IL-17, in contrast to IFN-γ, is indeed firmly 
linked with encepahlopathogenicity13, 14. Since IL-12, which was for many years believed to be 
the main pathogenicity-promoting factor in EAE, is no longer considered to be essential, we 
wanted to assess the involvement of IL-18 on TH1 polarization and EAE development. 
Interleukin (IL)-18 is a proinflammatory cytokine and a member of the IL-1 superfamily of 
cytokines. Its major function during inflammation appears to be associated with the polarization 
of TH cells15-17. IL-18 is a vital cofactor, together with IL-12, for the generation of IFN-γ-
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secreting TH1 cells. It is secreted by APCs and signals via the IL-18R, a heterodimer consisting of 
a ligand-binding IL-18Rα-subunit and a signaling IL-18Rβ-subunit (IL-1RAcPL; IL-1R7). 
Downstream signaling of the IL-18R, like that of other IL-1Rs and TLRs, activates IRAK4 and 
MyD8818-20. IL-18R is expressed on lymphocytes and has more recently been found to be 
expressed on accessory cells21-24. While it is firmly established that IL-18 can bind to the IL-18R 
complex, its affinity to IL-18Rα is only weak25, 26. The fact that IL-18-/- mice have been 
demonstrated to be EAE-resistant27, causes a dilemma given the clearly protective activity of IL-
1212, 28, 29 and IFN-γ30. Therefore, we sought to identify the mechanism by which IL-18 drives 
autoimmunity. 
Here we show that IL-18 does not exert a visible pathogenic effect in EAE and IL-18-/- mice are 
fully susceptible to EAE. However, deletion of its proposed receptor (IL-18Rα) results in 
complete resistance to EAE, suggesting the presence of an alternative ligand with 
encephalitogenic properties. Loss of IL-18Rα affects neither the priming nor expansion of Ag-
driven T cells. However, engagement of IL-18Rα on APCs is critical for the generation of TH17 
cells in an IL-23-dependent fashion. 
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Results 
Mice deficient in both IL-12p35 and IL-18 are fully susceptible to EAE 
EAE is generally referred to as a TH1-mediated disease yet deletion of IL-12p35, a major TH1-
promoting cytokine, renders mice susceptible to MOG-peptide-induced EAE12. Shi et al. have 
demonstrated, however, that mice deficient in IL-18, a cytokine that synergizes with IL-12 in TH1 
polarization, are resistant to EAE27. To assess whether IL-18 is capable of compensating for the 
loss of IL-12 in p35-/- mice, rendering them EAE susceptibility, we generated mice deficient in 
both IL-12p35 and IL-18 (p35-/-x IL-18-/-). Immunization with MOG35-55 emulsified in CFA 
showed that p35-/-x IL-18-/- mice are fully susceptible to EAE and have a similar disease severity 
and development as is seen in wt mice (Fig. 1a and Table 1). This demonstrates that IL-18 is not 
responsible for the EAE susceptibility of IL-12p35-/- mice and implies that IL-18 itself is a 
cytokine that has little or no effect on EAE pathogenesis. To confirm this, we actively immunized 
wt and single-mutant IL-18-/- mice with MOG peptide and found that IL-18-/- mice are indeed 
fully susceptible to EAE (Fig. 1b and Table 2).  
 
IL-18 is required for mitogen- but not Ag-driven immunity 
In order to rule out the possible expression of a truncated yet functional form of IL-18, we 
extensively verified the targeting strategy and genotype of the mice. We could clearly establish 
that IL-18-/- mice do not produce IL-18 mRNA by performing RT-PCR with primers located 
outside the target of deletion. We also analyzed by ELISA whether we could detect IL-18 
secreted from activated splenocytes derived from wt and IL-18-/- mice, which showed that IL-18-/- 
mice are indeed completely IL-18 deficient (Supplementary Fig. 1 online). As observed in many 
experimental systems, the deletion of IL-18 consistently results in the paucity of an IFN-γ 
response31, 32. We thus stimulated lymphocytes derived from naïve wt, IL-18-/- and, in addition, 
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IL-18Rα-/- mice in vitro with the lectin Concanavalin A (ConA) for 16 hours and IFN-γ 
production was subsequently measured by ELISA. Consistent with the principle that IL-18 has an 
effect on IFN-γ production, lymphocytes from both IL-18-/- and IL-18Rα-/- mice did not secrete 
IFN-γ in contrast to wt lymphocytes (Fig. 2a). We could further verify that T cell function and 
activation during polyclonal stimulation is not directly impaired as there was no difference in 
IFN-γ secretion by stimulated wt, IL-18-/- and IL-18Rα-/- purified CD4+ T cells (Supplementary 
Fig. 2 online). 
To establish the role of IL-18 and IL-18Rα in an adaptive Ag-driven immune response, we 
immunized wt, IL-18-/- and IL-18Rα-/- mice subcutaneously with MOG35-55 or KLH (as a large 
immunogenic protein Ag ≈ 400 kDa) in CFA and 7 days later isolated and restimulated 
lymphocytes with the cognate Ag in vitro. Surprisingly, when KLH was used, we did not observe 
a drastic difference in the IFN-γ-producing ability of lymphocytes derived from wt, IL-18-/- and 
IL-18Rα-/- mice (Fig. 2b). The less immunogenic MOG-peptide, however, revealed that IL-18Rα-
/- mice produced significantly less IFN-γ than wt or IL-18-/- mice. Our data support the notion that 
while IL-18 and IL-18Rs are critical co-factors for the early IFN-γ response of mitogen- or lectin- 
activated T cells, peptide-induced responses revealed discordant behavior between lymphocytes 
lacking IL-18 or IL-18Rα. On the other hand, activation and IFN-γ production through a complex 
large protein Ag appears to be independent of IL-18 or IL-18Rα, a concept that is in agreement 
with the recent report by Santos et al33. 
 
IL-18Rα-/- and anti-IL-18Rα mAb-treated mice are resistant to EAE  
Mice deficient in IL-18Rα have been described as having an immunological phenotype similar to 
that of IL-18-/- mice34. Given the discordant behavior of IL-18- and IL-18Rα-deficient 
lymphocytes towards MOG-peptide in recall-responses, we discovered that IL-18Rα-/- mice were, 
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in sharp contrast to both wt and IL-18-/- mice, resistant to EAE induction (Fig. 3a and Table 2). 
Histological analysis of spinal cords obtained 28 days after EAE induction showed that EAE-
susceptible wt and IL-18-/- mice incur significant inflammation and demyelination as revealed by 
H&E and LFB staining, respectively (Fig. 4). A more detailed analysis demonstrated the 
infiltration of T cells, macrophages and B cells and axonal damage in the spinal cords of these 
mice (Fig. 4 and Supplementary Fig. 3a online). In contrast, IL-18Rα-/- samples demonstrated 
no leukocyte infiltration or demyelination (Fig. 4 and Supplementary Fig. 3a online). 
Quantitative RNA analysis of spinal cords from mice with EAE showed that in accordance with 
the presence of inflammatory infiltrates, wt and IL-18-/- mice had increased expression of 
chemokines and inflammatory cytokines while these were decreased or absent in IL-18Rα-/- mice 
(Supplementary Fig. 3b online).  
The discordant behavior of IL-18-/- and IL-18Rα-/- mice with regards to EAE strongly points 
towards an additional IL-18Rα ligand with powerful encephalitogenic properties. In order to 
verify that IL-18Rα and IL-18 have independent biological functions, we blocked IL-18Rα in 
EAE-susceptible IL-18-/- mice. Treatment of IL-18-/- mice with anti-IL-18Rα mAbs, given 1 day 
pre-immunization and every 3 days thereafter until the end of the experiment, significantly 
reduced disease development (Fig. 3b). Administration of anti-IL-18Rα mAbs did not lead to 
deletion of IL-18Rα-expressing cells nor did it alter the composition of peripheral leukocytes in 
the blood, LN or spleen (Supplementary Table 1 online). Interestingly, treating IL-18-/- mice 
with mAbs against IL-18Rα post-immunization (day 10 p.i.) also abrogated EAE progression 
(Fig. 3c) suggesting that IL-18Rα engagement is an important event during the effector phase of 
EAE. Combining the facts that IL-18Rα blockade prevents EAE even in mice in which its ligand 
is completely removed by gene-targeting and that IL-18 has a reportedly low affinity to IL-18Rα, 
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we propose that another ligand must be responsible for the engagement, signaling and immune 
development mediated by IL-18Rα.  
 
IL-18Rα engagement is required for the persistence of inflammatory cells during the 
effector phase of disease and TH17 polarization 
EAE is characterized by a massive influx of inflammatory cells into the CNS at the peak of 
disease yet immune cells also invade the CNS prior to the onset of clinical symptoms35, 36. For 
example, recruitment of CD4+ T cells into the CNS is critical for the initiation of the effector 
phase of EAE while invasion of polymorphonuclear leukocytes appears to have a role in 
orchestrating these events37. Therefore, to establish the impact of IL-18Rα on the capacity of 
inflammatory cells to invade the CNS at time-points of pre-clinical disease, we immunized mice 
and analyzed the CNS for inflammatory infiltrates on day 7 post-immunization by flow 
cytometry. In contrast to peak disease when the IL-18Rα-/- CNS is devoid of inflammatory 
infiltrates (Fig. 4), IL-18Rα-/- leukocytes (CD45-high cells) were capable of CNS infiltration to 
the same extent as those of wt and IL-18-/- mice at stages of pre-clinical disease (Fig. 5a). 
Detailed analysis of the invading cells revealed that in wt, IL-18-/- and IL-18Rα-/- CNS 
comparable numbers of CD4+ T cells, granulocytes, macrophages and B cells were present 
(Supplementary Fig. 3c). Thus, IL-18Rα-/- inflammatory cells appear to be incapable of 
persisting or of maintaining CNS invasion during the effector phase of the disease. Interestingly, 
these results resemble data obtained in IL-23-/- mice, which are also resistant to MOG35-55-
induced EAE and in which the deficiency does not prevent infiltration of inflammatory cells into 
the CNS, as observed post-immunization but pre-disease onset13.  
The similarities between IL-18Rα-/- and IL-23-/- mice regarding their EAE resistance with 
concomitant inflammatory cell invasion into the CNS, provoked us to assess the impact of IL-
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18Rα on IL-17 production. IL-17 producing TH cells (TH17) are now widely held to be the main 
pathogenic population during autoimmune inflammation13, 14. Therefore, we quantified the 
number of IL-17 producing MOG-reactive T cells invading the CNS pre and post-clinical disease 
onset in mice immunized with MOG35-55. ELIspot analysis revealed that immediately prior to 
disease onset (9dpi), the number of MOG-specific IFN-γ-secreting cells invading the CNS is 
similar between EAE susceptible IL-18-/- and resistant IL-18Rα-/- mice, whereas TH17 cells are 
virtually absent from the CNS of IL-18Rα-/- mice (Fig. 5b). After disease onset, we could detect 
increased numbers of IFN-γ and IL-17-secreting cells from the susceptible IL 18-/- and wt mice, 
whereas they were virtually absent from the CNS of immunized IL-18Rα-/- mice (Fig. 5c).  
To determine whether IL-18Rα-/- mice are defective in generating IL-17-producing T cells, we 
analyzed IL-17 expression by freshly primed lymphocytes in vitro. We immunized wt, IL-18-/- 
and IL-18Rα-/- mice with either MOG35-55 peptide or KLH and harvested lymphocytes from the 
draining LNs after 7 days. We performed real-time PCR analysis of mRNA obtained from these 
lymphocytes upon restimulation with their cognate Ag and showed that the expression of IL-17 
mRNA is significantly decreased in IL-18Rα-/- cells in comparison to wt and IL-18-/- cells (Fig. 
6a). We could corroborate this by ELISA using the cell culture medium of lymphocytes 
rechallenged with their cognate Ag in vitro, which demonstrated that IL-17 production is 
significantly decreased in IL-18Rα-/- but not IL-18-/- or wt lymphocytes (Fig. 6b). In contrast to 
the production of IFN-γ, which shows some dependence on the immunogenicity of the Ag, IL-17-
secretion was consistently decreased even when KLH was used as the driving Ag. Thus, 
resistance of IL-18Rα-/- mice to EAE results apparently from their inability to generate TH17 
cells. 
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Expression of IL-18Rα on accessory cells is essential for encephalitogenicity 
The lack of IL-18Rα completely prevents the development of EAE and TH17 polarization, 
whereas its putative ligand IL-18 appears to be irrelevant. The cell type on which the IL-18Rα 
exerts its primary effects remains unknown. This is mainly due to the fact that IL-18Rs are 
expressed by various cell types and tissues21, 27, 38. However, one is likely to presume that the 
presence of IL-18Rα on CD4+ T cells is critical for the subsequent polarization of TH17 cells. In 
order to identify the cell and tissue location of the IL-18Rα lesion in EAE, we selectively 
expressed IL-18Rα on cells in the leukocyte compartment using irradiation bone-marrow (BM)-
chimeras. Following irradiation and reconstitution, the immune compartment in secondary 
lymphoid tissues of recipient mice is comprised of hematopoietic cells derived from donor 
mice39. We generated BM-chimeras by transferring either a 4:1 ratio of RAG-/- and IL-18Rα-/- 
BM into wt recipients (RAG-/- + IL-18Rα-/- → wt) or IL-18Rα-/- BM only into wt recipients (IL-
18Rα-/- → wt). Wt-BM was transferred into wt recipients as a control (wt → wt). RAG-/- mice do 
not have lymphocytes and the resulting chimera (RAG-/- + IL-18Rα-/- → wt) thus has an IL-
18Rα-deficient lymphocyte compartment, whereas the majority of all other leukocytes has 
undisrupted IL-18Rα alleles.  
As expected IL-18Rα-/- → wt mice were resistant to EAE upon immunization with MOG 
peptide (Fig. 7a). However, addition of BM from RAG-/- mice, which does not give rise to T or B 
cells and therefore expresses IL-18Rα only on accessory cells and not on lymphocytes, to IL-
18Rα-/- BM was able to overcome the resistance of IL-18Rα-/- mice to EAE (RAG-/- + IL-18Rα-/- 
→ wt) (Fig. 7a). Thus, IL-18Rα must exert its primary effects in the accessory cell (mono- and 
polymorphonucleated phagocytes, DCs & NK-cells) compartment. Again, this finding is 
unexpected, given that IL-18 is thought to exert its effects primarily on T cells and NK cells, but 
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it is completely consistent with the undisturbed T cell responses that we have thus far 
demonstrated (Supplementary Fig. 2 online).  
As IL-18Rα has been demonstrated to be present on myeloid cells40, we decided to assess the 
capacity of IL-18Rα-deficient APCs to prime naïve T cells. To do so, we purified CD4+ T cells 
from 2d2 mice that express a transgenic TcR specific for MOG35-55 and co-cultured them with 
mature, MOG-peptide-pulsed wt, IL-18-/- and IL-18Rα-/- BM-derived DCs. Measurement of their 
proliferation by thymidine incorporation showed no difference in the stimulatory abilities of IL-
18Rα-/- BM-DCs (Fig. 7b). To confirm this in an in vivo setting, we injected CFSE-labeled 2d2 
cells into wt, IL-18-/- and IL-18Rα-/- mice, immunized them with MOG35-55 and analyzed 
proliferation of 2d2 cells by flow cytometry after 4 days. Transferred 2d2 cells proliferated to the 
same extent in IL-18Rα-/- mice as in wt and IL-18-/- animals (Fig. 7c). Using adoptive transfer of 
TcR-Tg T cells, we were able to verify the notion that the IL-18Rα-deficiency lesions a non-
lymphocytic leukocyte and through this, the capacity to polarize TH17 cells (Supplementary Fig. 
4 online). With regards to the ability of myeloid cells to reach the CNS tissue, we generated 
mixed BM-chimeras of CD45-congenic wt and IL-18Rα-/- BM-donors into wt recipients and 
evaluated the capacity of myeloid populations to invade the CNS during disease. We confirmed 
that the mice carry a 1:1 ratio of wt and IL-18Rα-/- hematopoietic cells in the systemic 
compartment. Upon induction of EAE, both myeloid populations invade the CNS again at a 1:1 
ratio, implicating that there is no migratory defect of myeloid cells (data not shown). Lastly, 
expression of activation markers and co-stimulatory molecules by LPS-matured DCs showed no 
difference in upregulation of CD80, CD86 and CD40 between wt, IL-18-/- and IL-18Rα-/- mice 
(data not shown). 
To confirm the role and function of IL-18Rα signaling on accessory cells during the effector 
phase of EAE, we adoptively transferred encephalitogenic MOG-reactive T cells derived from wt 
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donor mice into both wt and IL-18Rα-/- recipient mice. Fully primed and activated 
encephalitogenic T cells derived from wt mice induced EAE in wt recipient mice, yet they were 
incapable of inducing clinical EAE in IL-18Rα-deficient hosts (Fig. 7d).  
 
IL-18Rα-deficient APCs show limited IL-12/23p40 secretion required for pathogenic TH17 
cell generation 
As restimulation with cognate Ag demonstrated a significant decrease in IL-17 production, we 
decided to analyze the capacity of APCs to secrete IL-12/23p40, which is necessary for the 
expansion of pathogenic TH17 cells. To determine p40 secretion, we stimulated T cell-depleted 
splenocytes with αCD40 mAb for 36 hours before analyzing p40 production by ELISA. We 
found that in contrast to high levels of p40 production by wt and IL-18-/- APCs, IL-18Rα-/-, 
similar to p40-/- APCs, showed impaired p40 production (Fig. 8a). Finally, we could validate the 
deficient IL-12/23p40 production in an adaptive immune response by restimulating LN 
preparations from MOG- and KLH-immunized mice in vitro and analyzing p40 production after 2 
days. As expected, there was a significant decrease in the production of p40 by IL-18Rα-/- 
lymphocytes as opposed to wt and IL-18-/- lymphocytes (Fig. 8b,c). We failed to observe a 
concrete decrease in p19 expression by αCD40-stimulated DCs, indicating that the effect of IL-
18Rα-deficiency on TH17 cells is likely regulated at the level of p40 rather than p19. In addition, 
we did not observe a decrease TGFβ expression in IL-18Rα-/- APC’s  (data not shown). Our data 
indicate that APC activation results in the production of an IL-18Rα ligand driving IL-23 
secretion by APCs. Therefore the resistance of IL-18Rα-/- mice to EAE seems to result from 
abrogated TH17 cell development, which is likely the consequence of poor p40 production by IL-
18Rα-/- APCs. 
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Discussion 
Organ-specific inflammatory diseases generally result from inappropriate expansion and 
activation of effector T lymphocytes, which are capable of escaping peripheral tolerance and 
reacting vividly to self-antigens. Until recently, TH1 lymphocytes were thought to represent the 
autoreactive T cells responsible for inducing cellular autoimmunity3-7. However, there is 
mounting evidence that TH17 cells, and not TH1 cells, are the pathogenic T cell effectors in 
autoimmunity and that their development is negatively regulated by both TH1 and TH2 
cytokines12-14, 28, 41-43. 
Due to the plethora of data arguing against the TH1 paradigm of autoimmunity, we were 
interested in characterizing the role of IL-18 in EAE. IL-18 synergizes with IL-12 in the 
differentiation of naïve TH cells into TH1 cells. Therefore, our goal was to determine if the EAE 
susceptibility of IL-12-/- mice occurs as a result of redundancy, whereby the continued presence 
and activity of IL-18 in these mice is sufficient for EAE induction. Our data dismiss this 
hypothesis as IL-12p35-/-x IL-18-/- double deficient mice are fully susceptible to EAE. On further 
analysis, we discovered that IL-18-/- mice are also fully susceptible to EAE. These data show that 
IL-18 does not compensate for the loss of IL-12, again supporting the notion that TH1 cells and 
TH1-inducing factors do not promote EAE development. These findings are not unexpected when 
taking into account the non-encephalitogenic effects of other TH1 cytokines and the discovery of 
pathogenic TH17 cells but they nevertheless contradict a previously published report27. We could 
rule out that the differential results were due to differences in reagents or alternative methods of 
immunization and most importantly the experiments were performed in the identical line of mice. 
Therefore we have so far been unable to elucidate the disparities between the two sets of results; 
yet in support of our findings, IL-18-/- mice have been shown to be fully susceptible to the 
development of experimental autoimmune uveitis (EAU)44, 45. Generally, the observations in 
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EAU with regards to gene-targeted mice match that of EAE. Additionally, a recent report directly 
supports our findings that IL-18 is unnecessary during Ag-induced TH1 responses, while 
demonstrating that IL-18 is redundant in an Ag-induced arthritis model33.   
Despite the susceptibility of IL-18-/- mice, we discovered that IL-18Rα-/- mice are resistant 
to EAE, which implies the existence of an alternative IL-18Rα-binding ligand with 
encephalitogenic properties. As the affinity of IL-18 to IL-18Rα is fairly poor and requires 
heterotrimerization with IL-18Rβ for increased affinity26, 46, the likelihood that there is another 
ligand with higher affinity for IL-18Rα is very high. There are a number of orphan receptors 
within the IL-1R superfamily and given the fact that these receptor subunits form heterodimers 
with one another47, it is most likely that IL-18Rα not only has different binding partners, but also 
different ligands. We demonstrated the potency of this putative ligand by significantly attenuating 
disease development in IL-18-/- mice using anti-IL-18Rα antibodies. Given that the accepted IL-
18Rα-ligand, IL-18, was not present in these mice and that their cellular constituents were not 
affected as a result of injecting the antibody, these results provide strong evidence for the 
existence of such an alternative IL-18Rα ligand and we are presently in the process of identifying 
this novel IL-18Rα-binding ligand as well as the composition of its receptor complex.  
The development of EAE is dependent on the infiltration of activated CD4+ T cells into 
the CNS, an event that is accompanied by the influx of other immune cells including B cells, 
macrophages and granulocytes35-37. Although inflammatory cells are clearly absent from the 
spinal cords of IL-18Rα-/- mice at the peak of clinical EAE, we could detect comparable CNS-
invading leukocyte infiltration prior to the onset of disease. Therefore, the lack of IL-18Rα does 
not affect the migratory properties of these cells but their ability to persist within or maintain 
infiltration into the target organ. Interestingly, the presence of inflammatory infiltrates in the IL-
18Rα-/- CNS without concomitant EAE susceptibility resembles the observations in IL-23-/- 
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mice48. The resistance of IL-23-/- mice to EAE likely results from their inability to expand 17-
producing TH cells13. TH17 cells are a novel TH cell subset and while TGFβ1 seems to be 
necessary for their de novo differentiation49-51, IL-23 has been suggested to be required for their 
survival and expansion49. We found that the MOG-reactive T cells invading the CNS of IL-18Rα-
/- mice immediately prior to clinical disease development did not produce IL-17, when compared 
to wt or IL-18-/- mice. Comparable to IL-23-deficient mice, we have discovered that IL-18Rα-/- 
mice are deficient in producing IL-17 at both the RNA and protein levels. 
Our goal was then to determine the mechanism of action of IL-18Rα activation and 
signaling during EAE, as the expression of IL-18Rα is broadly distributed21, 27, 38. As our previous 
experiments regarding T cell priming only focused on the development of TH1 cells, it seemed 
likely that the lack of TH17 cells resulted from the absence of IL-18Rα expression on this 
subpopulation of T cells. This was not the case, however, and we could demonstrate that the loss 
of IL-18Rα lesions an accessory cell without affecting the capacity of IL-18Rα-deficient TH-cells 
to develop an encephalitogenic phenotype. Furthermore, the importance of IL-18Rα on an 
accessory cell was accentuated in an adoptive transfer experiment whereby encephalitogenic wt T 
cells could not induce EAE in IL-18Rα-/- mice. The overall capacity to activate T cells and their 
expansion is not affected by the loss of IL-18Rα. In addition, expansion of T cells is not affected 
by the loss of IL-18Rα from DCs and IL-18Rα-deficient APCs show no difference in their 
activation status.  
Finally, we demonstrate that IL-18Rα signaling on APCs is critical for the secretion of IL-
23p40 and the subsequent production of IL-17. Our data thus support the hypothesis that IL-17 
secretion is dependent on the continuous support of TH17-promoting APCs, as adoptive transfer 
of encephalitogenic lymphocytes into IL-18Rα-/- mice renders the cells incapable of causing 
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tissue damage. This also explains the ability of anti-IL-18Rα antibodies to prevent disease in IL-
18-/- mice even after priming has occurred.  
In summary, we provide additional evidence refuting the TH1 paradigm of autoimmunity 
by demonstrating a non-pathogenic role for IL-18 in EAE. In contrast, however, the so-called IL-
18Rα is critical for the development of EAE thus implying the presence of an alternative IL-
18Rα-binding ligand. We show that IL-18Rα signaling on APCs is critical for IL-23p40 
secretion and the ensuing development of encephalitogenic TH17 cells thereby explaining the 
resistance of IL-18Rα-/- to MOG35-55-induced EAE. The identification of the alternative IL-18Rα-
binding ligand should provide a potent novel therapeutic approach for the treatment of organ-
specific inflammatory diseases such as MS. The attractive feature of this IL-18Rα pathway for 
therapeutic targeting is that its loss does not completely suppress immunity, but rather 
specifically affects the behavior of pathogenic autoimmune effector T cells. 
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Methods  
Mice:  Female C57BL/6 mice were purchased from Harlan Laboratories (Netherlands). IL-
12p40-/- mice were purchased from Jackson Laboratories (USA). Homozygous IL-18-/- and IL-
18Rα-/- (all backcrossed onto C57BL/6 for more than 12 generations) were provided by S. Akira 
(Osaka) and Rag1-/- mice were provided by R. Zinkernagel (Zurich) and were bred in house under 
specific pathogen free (spf) conditions. 2d2 (MOG-TcR-Tg) mice were provided by V. Kuchroo 
(Harvard Medical School, Boston, MA) Animal experiments and breeding were approved by the 
Swiss Veterinary Office (#69/2003 and #70/2003). 
Irradiation Bone Marrow (BM)-chimeric mice were generated as described52. Briefly, BM-donor 
mice were euthanized using CO2 and BM-cells were isolated by flushing femur, tibia, radius and 
hip bones with phosphate buffered solution (PBS). BM cells were then passed through a 100 µm 
cell strainer and cells were washed with PBS. Recipient mice were lethally irradiated with 1100 
rads (split dose) and i.v. injected with 12-25x106 BM-cells. Engraftment took place over 8 weeks 
of recovery.  
 
Induction of EAE: Mice were immunized subcutaneously with 200 µg of MOG35-55 peptide 
(amino acid sequence: MEVGWYRSPFSRVVHLYRNGK), obtained from GenScript 
(Piscataway, NJ), emulsified in CFA (DIFCO, Detroit, MI). Mice received 200 ng pertussis toxin 
(PtX) (Sigma-Aldrich) intraperitoneally at the time of immunization and 48 hours later. For 
adoptive transfer, MOG-reactive T cells were generated as described39. Monoclonal α-IL-18Rα 
antibody (clone 112624) (R&D Systems) was administered either 1 day pre-immunization (450 
µg/mouse) and every 3 days thereafter (300 µg/mouse) or every 3 days beginning from disease 
onset (300 µg/mouse). Mice were scored daily as follows: 0) no detectable signs of EAE; 0.5) 
distal tail limp; 1) complete tail limp; 2) unilateral partial hind limb paralysis; 2.5) bilateral partial 
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limb paralysis; 3) complete bilateral hind limb paralysis; 3.5) complete hind limb paralysis and 
unilateral forelimb paralysis; 4) total paralysis of fore and hind limbs (score > 4 to be 
euthanized); 5) death. Each time point shown is the average disease score of each group. 
Statistical significance was assessed using an unpaired Student’s t-Test (∗ < 0.05; # < 0.01). 
 
Histology and flow cytometry: Mice were euthanized with CO2, followed by perfusion with 
PBS and subsequent perfusion with 4% paraformaldehyde (PFA) in PBS. The spinal column was 
removed and fixed in 4% PFA in PBS. The spinal cord was then dissected and paraffin-embedded 
prior to staining with either haematoxylin & eosin or CD3, B220 and MAC-3 antibodies (BD 
Pharmingen) to assess infiltration of inflammatory cells, luxol fast blue to determine the degree of 
demyelination or amyloid precursor protein to assess the extent of axonal damage. 
For cytofluorometric analysis we used the following antibodies: αCD45, αCD4, αVα3.2, 
αCD11b, αGR1, and αB220 (BD Pharmingen). For analysis of CNS invading cells, mice were 
euthanized with CO2 and perfused intracardially with PBS as described52. Spinal cord was 
flushed out with PBS and the brain was dissected to isolate the brainstem. Both tissues were 
homogenized and strained through a 100µm nylon filter (Fisher). After centrifugation the cell 
suspension was resuspended in 30% Percoll (Pharmacia) and centrifuged at 12,000 rpm for 30 
min at 4°C. We collected the interphase cells and extensively washed them before staining. For 
flow cytometry, we incubated the antibody for 20 min at 4°C. We analyzed the cells using a 
FACSCalibur (BD Pharmingen) with CellQuest software. Post-acquisition analysis was 
performed using WinMDI 2.8 software (Scripps-Research Institute). 
 
Proliferation and cytokine assays: Spleen, axillary and inguinal lymph nodes were isolated 
from naïve mice or mice primed by injections of 100 µg/flank of MOG35-55 or KLH (Sigma) 
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emulsified in CFA 7 days earlier. 2x105 cells were placed as triplicates in 96-well plates. For 
naïve cells, 5µg/ml ConA was used for stimulation for 16 hours and 5µg/ml αCD40 (FGK) was 
used for stimulation for 36 hours before analyzing cytokine production by ELISA. CD4+ T cells 
were purified from naïve splenocytes using BD IMag Magnetic Beads (BD Pharmingen) and 
stimulated with 5 µg/ml αCD3 (2c11) and 5 µg/ml αCD28 (37N) for 36 hours before analyzing 
IFN-γ production by ELISA. MOG35-55 or KLH reactive cells were stimulated in triplicate for 48 
hours with either 50 µg/ml MOG35-55 or KLH, 5 µg/ml ConA or medium and 0.5 µCi/ml 3[H]-
thymidine was added after 24 hours to observe proliferative responses. Thymidine incorporation 
was assessed using a Filtermate Harvester and a scintillation and luminescence counter. For 
cytokine analysis, the culture supernatant of identical sister cultures was harvested after 48 hours 
and analyzed in duplicate for IFN-γ, IL-17 and IL-23p40 production by ELISA (Pharmingen, La 
Jolla, CA). For real-time PCR analysis, RNA was isolated from restimulated cells by TRIzol 
extraction (Invitrogen). 
ELIspot: For ELIspot assays, lymphocytes were isolated from the CNS of MOG35-55-immunized 
mice on days 9 and 14 dpi by differential percoll centrifugation as described above. 2 x 105 cells 
were plated in complete RPMI containing 50 µg/ml MOG35-55 in 96-well plates (Millipore) coated 
with 7.5 µg/ml αIFN-γ (AN18; Mabtech) or 2 µg/ml αIL-17 (TC11-18H10; BD Pharmingen) 
Abs. The plates were incubated at 37°C, 5% CO2 for 18 (IL-17) or 20 (IFN-γ) hours at which 
point cells were discarded and plates were washed with PBS. 0.5 µg/ml αIFN-γ-bio (R4-6A2; 
Mabtech) or 1 µg/ml αIL-17-bio (TC11-8H4.1; BD Pharmingen) Abs were added and incubated 
at RT for 2 and 4 hours, respectively. After washing, streptavidin-alkaline phosphatase (Mabtech) 
was added to the plate and incubated for 1 hour at RT. The plates were washed with PBS and 100 
µl of the substrate solution BCIP/NBT-plus was added to the wells and developed until distinct 
spots emerged. The plates were analyzed using an elispot reader (CTL immunospot). 
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Generation of BM-derived DCs: BM-derived DCs were generated as described53. Briefly, BM-
donor mice were euthanized using CO2 and the femur and tibia were removed. BM-cells were 
isolated by flushing the bones with PBS and were filtered through a 100µm cell strainer. Cells (2-
2.5x106 in 10 ml) were cultured in RMPI containing 10% FCS with the addition of 10% 
conditioned medium obtained from GM-CSF-transfected X-63 cells (obtained from A. Rollink, 
University of Basle, Switzerland). After at least 6 days, BM-derived DCs were matured with 
1µg/ml LPS overnight while immature BM-derived DC’s were maintained in GM-CSF-
containing medium. BM-derived DCs were used from day 7 to 9.  
 
Tg T cell proliferation and polarization: For in vitro proliferation of transgenic T cells, spleens 
were harvested from naïve 2d2 mice and CD4+ T cells were purified using BD-IMag magnetic 
beads (BD Pharmingen). The purity of T cell isolation was verified by FACS analysis. 1x105 2d2 
T cells were cultured in a 96-well plate together with 3,000-10,000 immature or mature BM-DCs. 
Prior to co-culture, BM-DCs were pulsed with 1 µg/ml MOG35-55 in RPMI for 3 hours, followed 
by washing and irradiation with 2000 rads. Non-pulsed DCs were used as a control as well as T 
cells cultured alone. Cells were incubated for 4 days and 3[H]-thymidine was added for the last 18 
hours of culture. 
For in vivo proliferation of TcR Tg cells, mice were injected i.v. with 25x106 10µM CFSE 
(carbofluorescein diacetate succinimidyl ester) (Invitrogen-Molecular Probes)-labeled 2d2 cells 
and immunized s.c. by bilateral flank injection of 100µg MOG35-55 emulsified in CFA. After 4 
days, mice were killed and LN cells were isolated and stained with an antibody against the MOG-
Tg TCR, αVα3.2, prior to cytofluorometric analysis. 
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Figure 1  
 
IL-18 is not required for EAE induction. EAE was induced by subcutaneous immunization with 
MOG35-55 emulsified in CFA. Data display the mean EAE score of each group. (a) EAE 
progression in p35-/-x IL-18-/- double deficient and wt mice. Shown is one representative of 2 
experiments (n ≥ 5 mice/group). (b) EAE progression in wt and IL-18-/- mice. Shown is one 
representative of 3 individual experiments.  
 
Figure 2 
IL-18 is required for mitogen-, but not Ag driven TH1 development. (a) ELISA assessing IFN-γ 
secretion by naïve wt, IL-18-/- and IL-18Rα-/- LN cells, stimulated for 16 hours with 5 µg/ml 
ConA or medium. (b) ELISA of IFN-γ in supernatant from mice immunized with 200 µg MOG35-
55 or KLH in CFA. 7 days after immunization, LN cells were isolated and restimulated in 
duplicate with either 50 µg/ml MOG35-55 or KLH and medium for 48 hours. Data are 
representative of at least 2 individual experiments and combine 2 mice in each group. 
 
Figure 3 
Discordant behavior of IL-18-/- and IL-18Rα-/- mice in EAE. EAE was induced by subcutaneous 
immunization with MOG35-55. Data display the mean EAE score of each group. (a) EAE 
progression in wt, IL-18-/- and IL-18Rα-/- mice. Shown is one representative of 3 individual 
experiments. (b) IL-18-/- mice were treated with 450 µg α-IL-18Rα Ab or control IgG 1 day pre-
immunization with MOG35-55 and with 300 µg antibody for every 3 days thereafter. (c) IL-18-/- 
mice were immunized and treated with 300 µg α-IL-18Rα Ab or control IgG at the first sign of 
disease. Shown are representatives of at least two individual experiments (n ≥ 5 mice/group).  
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Figure 4 
Histopathological analysis of IL-18-/- and IL-18Rα-/- mice.  Paraffin-embedded spinal cord 
sections from PBS-perfused wt, IL-18-/- and IL-18Rα-/- animals on day 28 after induction of EAE 
with MOG35-55. Haematoxylin and eosin (H&E) assesses cell infiltration, luxol fast blue (LFB) 
assesses demyelination, MAC3+, CD3+ and B220 stainings demonstrate macrophage, T cell and 
B cell infiltration, respectively, and amyloid precursor protein (APP) assesses axonal damage. 
Scale bar = 100µm, scale bar for CD3 and B200 inserts = 50µm, scale bar for APP inserts = 
25µm. 
 
Figure 5 
Tissue invasion at pre-clinical stages is not affected by IL-18Rα. Wt, IL-18-/- and IL-18Rα-/- were 
actively immunized with MOG35-55 and at different time-points, the cerebelli and spinal cords 
were isolated. CNS mononucleated cells were isolated as described in M&M. (a) CNS-derived 
leukocytes were obtained from mice 7 dpi, stained with CD45 and CD11b and analyzed by flow 
cytometry. CD45hi cells represent cells invading the CNS, CD45lo cells represent CNS-residents. 
Shown is one representative of 3 individual experiments. (b,c) IFN-γ and IL-17 ELIspot analyses 
of CNS-derived MOG-reactive lymphocytes restimulated for 18-20 hours with MOG35-55. Data in 
the bar graphs represent at least 2 individual experiments and combine 2 mice in each group. 
Shown is the mean ± S.E.M.  
 
Figure 6 
TH17 induction is dependent on IL-18Rα but not IL-18. Wt, IL-18-/- and IL-18Rα-/- mice were 
immunized with MOG35-55 or KLH in CFA and 7 days later, LN cells were isolated and 
restimulated for 48h with 50 µg/ml MOG35-55 or KLH. Data are representative of 2 individual 
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experiments combining at least 2 mice per group. Shown is the mean ± S.E.M. (a) Real-time PCR 
analysis of IL-17 mRNA expression by wt, IL-18-/- and IL-18Rα-/- lymphocytes. Results are 
normalized to β-actin expression and analyzed in duplicate. (b) ELISA of IL-17 protein 
expression by MOG35-55 and KLH-restimulated lymphocytes, analyzed in duplicate.  
 
Figure 7  
The absence of IL-18Rα specifically lesions accessory cells but not lymphocytes. (a) EAE 
progression in IL-18Rα-/- → wt, IL-18Rα-/- + RAG-/- → wt and wt → wt bone-marrow chimeric 
mice actively immunized with MOG35-55 peptide. Shown is one representative of 2 individual 
experiments (n ≥ 5 mice/group). (b) BM-derived DCs were generated from wt, IL-18-/- and 
IL18Rα-/- mice, matured with 10 µg/ml LPS and subsequently pulsed with 1 µg/ml MOG peptide. 
2d2-specific CD4+ T cells were purified from naïve 2d2 mice and co-cultured with the peptide-
pulsed, irradiated DCs for 3 days. Proliferation was assessed by the incorporation of 3[H]-
thymidine during the final 24 h in triplicate wells. (c) In vivo proliferation of 2d2-transferred cells 
into wt, IL-18-/- and IL-18Rα-/- mice. 25x106 CFSE-labeled 2d2 mice-derived splenocytes were 
injected i.v. into recipient mice, which were subsequently immunized with MOG35-55 in CFA. 4 
days later, LNs were isolated, cells were stained with Vα3.2 and the proliferation of 2d2 cells was 
analyzed by flow cytometry. (d) A polyclonal population of MOG-reactive lymphocytes was 
generated as described52. EAE was induced in recipient mice by the adoptive transfer of 25x106 
MOG-reactive lymphocytes into IL-18Rα-/- and wt mice. Shown is one representative of 2 
individual experiments (n ≥ 5 mice/group). 
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Figure 8 
IL-18Rα engagement promotes the production of IL-23p40. (a) ELISA of IL-12/23p40 
production in the supernatant of T-cell depleted naive wt, IL-18-/- and IL-18Rα-/- splenocytes 
stimulated with 5 µg/ml αCD40 mAb for 36 hours. (b) ELISA of p40 expression in supernatant of 
LN cells from wt, IL-18-/- and IL-18Rα-/- mice immunized with MOG35-55 in CFA, isolated 7 days 
later and restimulated with 50µg/ml MOG35-55 or medium for 48 hours. (c) ELISA of p40 
expression in supernatant of LN cells from wt, IL-18-/- and IL-18R-/- mice immunized with KLH 
in CFA, isolated 7 days later and restimulated with 50µg/ml KLH or medium for 48 hours. 
Shown is the mean ± S.E.M. Data are representative of 2 individual experiments combining at 
least 2 mice per group. 
 
Table 1 
Analysis of EAE onset and severity in wt and p35-/-x IL-18-/- double-deficient mice. EAE was 
induced in wt and p35-/-x IL-18-/- mice by subcutaneous immunization with MOG35-55. Shown is 
disease incidence, mean day of onset and mean clinical score of diseased animals. 
 
Table 2 
Analysis of EAE onset and severity in wt, IL-18-/- and IL-18Rα-/- mice. EAE was induced in wt, 
IL-18-/- and IL-18Rα-/- mice by subcutaneous immunization with MOG35-55. Shown is disease 
incidence, mean day of onset and mean clinical score of diseased animals. 
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Supplementary Figure 1 
IL-18-/- LN cells do not produce IL-18. ELISA assessing IL-18 secretion by naïve wt and IL-18-/- 
LN cells, stimulated for 16 hours with the indicated stimuli of 1 µg/ml LPS, 100 U/ml IFN-γ, 5 
µg/ml ConA and 2.5 ng/ml IL-12. Error bars represent ± S.E.M. 
Supplementary Figure 2 
CD4+ T cells from IL-18-/- and IL-18Rα-/- mice are capable of IFN-γ production. CD4+ T were 
purified from naïve wt, IL-18-/- and IL-18Rα-/- splenocytes by magnetic cell sorting and were 
stimulated with αCD3 mAb or a combination of αCD3 and αCD28 mAbs for 36 hours in vitro. 
IFN-γ secretion by stimulated cells was determined by ELISA. Error bars represent ± S.E.M. 
Data are representative of at least 2 individual experiments. 
 
Supplementary Figure 3 
Analysis of inflammatory infiltrates, cytokines and chemokines in MOG35-55-immunized mice. (a) 
Quantification of CD3+, MAC3+, B220+ and APP+ cells in histological sections of spinal cord 
from actively immunized wt (n=8), IL-18-/- (n=5) and IL-18Rα-/- (n=4) mice 28 days post-
immunization. (b) Real-time PCR analysis of chemokine and inflammatory cytokine mRNA 
expression in the spinal cords of MOG35-55-immunized wt, IL-18-/- and IL-18Rα-/- mice 14 days 
post-immunization. (c) Quantification of CNS-invading leukocytes of MOG35-55-immunized wt, 
IL-18-/- and IL-18Rα-/- mice 7 days post-immunization, pre-disease onset. Leukocytes were 
isolated from the CNS of mice using Percoll and were stained with αCD45, αCD11b, αGR1, 
αB220 and αCD4 Abs to assess the percentage of macrophages, granulocytes, B cells and CD4+ 
T cells infiltrating the CNS by flow cytometry. 
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Supplementary Figure 4 
Intracellular staining for IL-17 and IFN-γ. Mice were injected with 25x106 OVA-specific TcR Tg 
OT-II splenocytes i.v. and immunized with 200µg OVA protein. 5 days later, lymphocytes were 
isolated and restimulated with 50 ng/ml PMA and 500 ng/ml ionomycin for 5 hours. Numbers in 
quadrants indicate the percent of cells staining positive for the indicated cytokines. 
 
Supplementary Table 1 
α-IL-18Rα Ab does not affect the composition of the peripheral immune compartment. IL-18-/- 
mice were subcutaneously immunized with MOG35-55 and treated with anti-IL-18Rα Ab or IgG. 
The composition of leukocytes in LNs, spleen and blood was analyzed 7 days later by flow 
cytometry. Shown is the percentage of leukocytes and accessory cells in LN cells, which is 
representative of spleen and blood. 
Figure 1
C
li
n
ic
a
l 
s
c
o
re
Days post-immunization
a                                                                       b
0
1
2
3
9 14 19 24
Wt Wt
IL-18-/-
C
li
n
ic
a
l 
s
c
o
re
0
1
2
3
9 13 19 24
p35-/-x IL-18-/-
Days post-immunization
Mouse            Incidence        Mean day of       Mean maximal clinical
genotypes      (%)       disease onset         score (+/- SEM)*
Wt           8/10 (80)              14.2       2.4   +/-   0.25
p35-/-x IL-18-/- 7/10 (70)              14.1       3.2   +/-   0.08 
p35-/-x IL-18-/- mice are susceptible to active EAE 
Table 1
* of diseased animals
Figure 2
a                               
b                                                                                                                    
IF
N
-γ
 (
n
g
/m
l)
+ ConA    - ConA
0
0.2
0.4
0.6
0.8
1
P < 0.002
Wt
IL-18-/-
IL-18Rα-/-
IF
N
-γ
 (
n
g
/m
l)
IF
N
-γ
 (
n
g
/m
l)
0
2
4
6
8
10
+ KLH                       - KLH+ MOG                     - MOG
0
200
400
600
800
P = 0.001
Mouse Incidence Mean day of Mean maximal
genotypes (%) disease onset clinical score (+/- SEM)*
Wt 17/20 (85) 11.8 2.6 +/- 0.13
IL-18-/- 20/22 (91) 12.8 2.35 +/- 0.13
IL-18Rα-/- 2/20 (10) 18.5 2.6 +/- 0.12
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